CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary

Reka Varnai, C. Sipeky, Lajos Nagy, Sandor Balogh, Bela Melegh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The purpose of this work was to investigate the contribution of CYP2C9 and VKORC1 to acenocoumarol (AC) dose variability, bleeding events in Hungary. The study recruited 117 patients on long-term AC therapy (INR 2–3), and 510 healthy individuals to model the findings. Patients were genotyped for alleles proved to affect lower AC overdose CYP2C9*2, CYP2C9*3, VKORC1*2. Additionally, we tested VKORC1*3, VKORC1*4 to examine their effect in patients with higher AC requirements. Most impact on dose reduction is accountable for CYP2C9*2/*3 (59%) and for VKORC1*2/*2 (45.5%), and on dose increase for newly evaluated VKORC1*3/*4 (22.5%) diplotypes. VKORC1*3 and *4 alleles seem to balance the dose-reducing effect of VKORC1*2 allele. Being a carrier of combination of VKORC1*2 and CYP2C9*2,*3 polymorphisms, rather than of one of these SNPs, is associated with higher risk of over-anticoagulation (up to 34.3%) in long-term AC treatment. The pharmacogenetic dosing algorithm involving VKORC1, CYP2C9 diplotypes and age explains 30.4% of AC dosing variability (p < 6.10 × 10−9). Correlation between the studied diplotypes and bleeding events could not be revealed.

Original languageEnglish
Pages (from-to)282-289
Number of pages8
JournalEnvironmental Toxicology and Pharmacology
Volume56
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Acenocoumarol
Hungary
Safety
Alleles
Therapeutics
Hemorrhage
International Normalized Ratio
Pharmacogenetics
Polymorphism
Single Nucleotide Polymorphism
Cytochrome P-450 CYP2C9

Keywords

  • Acenocoumarol
  • Bleeding event
  • CYP2C9
  • Dose
  • Hungary
  • VKORC1

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Health, Toxicology and Mutagenesis

Cite this

CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment : implication for clinical practice in Hungary. / Varnai, Reka; Sipeky, C.; Nagy, Lajos; Balogh, Sandor; Melegh, Bela.

In: Environmental Toxicology and Pharmacology, Vol. 56, 01.12.2017, p. 282-289.

Research output: Contribution to journalArticle

@article{68803dcb92c94db1929e43b54fc29af6,
title = "CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary",
abstract = "The purpose of this work was to investigate the contribution of CYP2C9 and VKORC1 to acenocoumarol (AC) dose variability, bleeding events in Hungary. The study recruited 117 patients on long-term AC therapy (INR 2–3), and 510 healthy individuals to model the findings. Patients were genotyped for alleles proved to affect lower AC overdose CYP2C9*2, CYP2C9*3, VKORC1*2. Additionally, we tested VKORC1*3, VKORC1*4 to examine their effect in patients with higher AC requirements. Most impact on dose reduction is accountable for CYP2C9*2/*3 (59{\%}) and for VKORC1*2/*2 (45.5{\%}), and on dose increase for newly evaluated VKORC1*3/*4 (22.5{\%}) diplotypes. VKORC1*3 and *4 alleles seem to balance the dose-reducing effect of VKORC1*2 allele. Being a carrier of combination of VKORC1*2 and CYP2C9*2,*3 polymorphisms, rather than of one of these SNPs, is associated with higher risk of over-anticoagulation (up to 34.3{\%}) in long-term AC treatment. The pharmacogenetic dosing algorithm involving VKORC1, CYP2C9 diplotypes and age explains 30.4{\%} of AC dosing variability (p < 6.10 × 10−9). Correlation between the studied diplotypes and bleeding events could not be revealed.",
keywords = "Acenocoumarol, Bleeding event, CYP2C9, Dose, Hungary, VKORC1",
author = "Reka Varnai and C. Sipeky and Lajos Nagy and Sandor Balogh and Bela Melegh",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.etap.2017.10.003",
language = "English",
volume = "56",
pages = "282--289",
journal = "Environmental Toxicology and Pharmacology",
issn = "1382-6689",
publisher = "Elsevier",

}

TY - JOUR

T1 - CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment

T2 - implication for clinical practice in Hungary

AU - Varnai, Reka

AU - Sipeky, C.

AU - Nagy, Lajos

AU - Balogh, Sandor

AU - Melegh, Bela

PY - 2017/12/1

Y1 - 2017/12/1

N2 - The purpose of this work was to investigate the contribution of CYP2C9 and VKORC1 to acenocoumarol (AC) dose variability, bleeding events in Hungary. The study recruited 117 patients on long-term AC therapy (INR 2–3), and 510 healthy individuals to model the findings. Patients were genotyped for alleles proved to affect lower AC overdose CYP2C9*2, CYP2C9*3, VKORC1*2. Additionally, we tested VKORC1*3, VKORC1*4 to examine their effect in patients with higher AC requirements. Most impact on dose reduction is accountable for CYP2C9*2/*3 (59%) and for VKORC1*2/*2 (45.5%), and on dose increase for newly evaluated VKORC1*3/*4 (22.5%) diplotypes. VKORC1*3 and *4 alleles seem to balance the dose-reducing effect of VKORC1*2 allele. Being a carrier of combination of VKORC1*2 and CYP2C9*2,*3 polymorphisms, rather than of one of these SNPs, is associated with higher risk of over-anticoagulation (up to 34.3%) in long-term AC treatment. The pharmacogenetic dosing algorithm involving VKORC1, CYP2C9 diplotypes and age explains 30.4% of AC dosing variability (p < 6.10 × 10−9). Correlation between the studied diplotypes and bleeding events could not be revealed.

AB - The purpose of this work was to investigate the contribution of CYP2C9 and VKORC1 to acenocoumarol (AC) dose variability, bleeding events in Hungary. The study recruited 117 patients on long-term AC therapy (INR 2–3), and 510 healthy individuals to model the findings. Patients were genotyped for alleles proved to affect lower AC overdose CYP2C9*2, CYP2C9*3, VKORC1*2. Additionally, we tested VKORC1*3, VKORC1*4 to examine their effect in patients with higher AC requirements. Most impact on dose reduction is accountable for CYP2C9*2/*3 (59%) and for VKORC1*2/*2 (45.5%), and on dose increase for newly evaluated VKORC1*3/*4 (22.5%) diplotypes. VKORC1*3 and *4 alleles seem to balance the dose-reducing effect of VKORC1*2 allele. Being a carrier of combination of VKORC1*2 and CYP2C9*2,*3 polymorphisms, rather than of one of these SNPs, is associated with higher risk of over-anticoagulation (up to 34.3%) in long-term AC treatment. The pharmacogenetic dosing algorithm involving VKORC1, CYP2C9 diplotypes and age explains 30.4% of AC dosing variability (p < 6.10 × 10−9). Correlation between the studied diplotypes and bleeding events could not be revealed.

KW - Acenocoumarol

KW - Bleeding event

KW - CYP2C9

KW - Dose

KW - Hungary

KW - VKORC1

UR - http://www.scopus.com/inward/record.url?scp=85031710789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031710789&partnerID=8YFLogxK

U2 - 10.1016/j.etap.2017.10.003

DO - 10.1016/j.etap.2017.10.003

M3 - Article

C2 - 29055218

AN - SCOPUS:85031710789

VL - 56

SP - 282

EP - 289

JO - Environmental Toxicology and Pharmacology

JF - Environmental Toxicology and Pharmacology

SN - 1382-6689

ER -